Tarsus Pharmaceuticals’ (TARS) Buy Rating Reaffirmed at Guggenheim

Tarsus Pharmaceuticals (NASDAQ:TARS)‘s stock had its “buy” rating restated by analysts at Guggenheim in a research report issued on Monday,Benzinga reports.

Several other brokerages also recently issued reports on TARS. The Goldman Sachs Group raised their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Finally, Barclays boosted their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $56.00.

Tarsus Pharmaceuticals Stock Down 3.0 %

Shares of Tarsus Pharmaceuticals stock traded down $1.46 on Monday, reaching $46.39. 79,849 shares of the company were exchanged, compared to its average volume of 592,494. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -12.26 and a beta of 1.01. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a one year low of $20.08 and a one year high of $57.28. The company has a 50-day moving average of $51.87 and a 200 day moving average of $42.75.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TARS. Crowley Wealth Management Inc. acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $44,000. R Squared Ltd bought a new position in Tarsus Pharmaceuticals in the 4th quarter valued at approximately $53,000. FMR LLC boosted its position in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after buying an additional 3,537 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth $166,000. 90.01% of the stock is owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.